# A truly interesting talk from Gilead's Patrick Loerch on creating real AI value in Biopharma at ...

> At BiotechX in Basel, Gilead's Patrick Loerch outlined what it really takes for AI to create value in biopharma — from systemic business impact to decision-making influence. I found his take on centralized vs. distributed AI models, regulatory coordination, and clinical value chain opportunities particularly compelling.

URL: https://www.ch-healthtech.com/insights/truly-interesting-talk-gileads-patrick-loerch-creating-real-ai-value-biopharma
Markdown: https://www.ch-healthtech.com/insights/truly-interesting-talk-gileads-patrick-loerch-creating-real-ai-value-biopharma.md
Published: 2024-10-09
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/artificial-intelligence, industry/large-pharma, function/innovation-management, function/digital-transformation, function/regulatory-compliance, geography/switzerland

---


A truly interesting talk from Gilead's Patrick Loerch on creating real AI value in Biopharma at BiotechX in Basel

Three things you need for AI to succeed:

- systemic business impact
- measurable value
- decision-making influence

It is still unclear whether a centralized CoE type model or a more distributed model for AI expertise works better, with Patrick advocating for a mixed model. Same applies for decision making.

Increasing regulation requires a coordinated response within big pharma companies.

Significant opportunities exist within a lot of use cases in the clinical value chain, including faster decision making, faster execution, and better data generation.